2017-03-008 - QDDP - Quantum Dots-based Diagnostics Platform

Kit for the diagnosis of different illnesses, based on hydrolytic properties of a biomarker (enzyme). A system of two populations of silica-embedded Quantum Dots (QD) (one of them quantifies the biomarker, the other is used as reference internal standard) are attached to a peptide sequence that incorporates a fluorescent colorant. A biomarker associated to the presence of a disease cleaves the peptidic linker, changing the fluorescent emission of the QDs proportionally to its concentration. Initial tests were performed with trypsin in stool samples as a biomarker for Cystic Fibrosis (CF).

Contacts

FB

Fernando Bravo
Institut Català d'Investigació Química (ICIQ)

Acronim & Gínjol codes

ACRONYM

QDDP

2017-03-008

Main technology offer

New platform for the quantitative measurement of hydrolytic enzymes

Public Partners

Centres CERCA List
Other Public Agents

Readiness Level

1-2 Research /
3-4 Experimental PoC /
5 Prototype /
6-7 MVP /
8 Industrialization /
9 Commercialization

MIN

1

2

3

4

5

6

7

8

9

10

MAX

1-First Canvas / 2-Market Analysis / 3-First Validation / 4-MVP / 5-Market Fit / 6-Validate Sales / 7-Final MPV / 8-Validate Business Model / 9-Key Metrics

MIN

1

2

3

4

5

6

7

8

9

10

MAX

1-Market hypothesis / 2-Basic Market / 3-PoC / 4-Target Customer / 5- Customer Validation / 6-Launchable MVP / 7-Customer feedback / 8-Scale product-service / 9-Sustainable business

MIN

1

2

3

4

5

6

7

8

9

10

MAX

Impact: ESG & SDG Goals

Sustainable Development Goals

Focus on minoritary diseases Fast diagnosis at point of care, to improve diagnosis in underdeveloped countries

Faster and cheaper diagnosis (of Cystic Fibrosis) Portable diagnosis (of Cystic Fibrosis)

Market Data

Fast, selective and preferentially non-invasive methods are required to the diagnosis of diseases. F. ex., CF is diagnosed in patients after a series of sequential tests, which is time and resource consuming, and may require an expert to interpret the results. We propose the use of a portable test that could be used in primary attention centers, which can quantify with high level of accuracy a biomarker associated to CF within minutes, and which, potentially, can also identify the CF gene carriers (heterozygote). The technology can be potentially applied to diagnosis of other diseases, such as pneumonia.

512000000000

23000000000

1000000000

B2B. Licensing of technology to healthcare measurement device manufacturer.

Fast, portable, reliable diagnosis

Desease diagnostics; health system

DeepTech Area

Technology Status

The technology consists of ratiometric FRET based nanosensors, and incorporates one population of QD acts as internal reference to enable calibration. Another QD population, with distinctive fluorescence pattern, is used to quantify the biomarker.

Regulatory Precision and cost effectiveness of current diagnosis Insufficient, non-reliable data

The technology has been abandoned due to: insufficient stability of the QDs and reliability of the results; small market for CF diagnosis; insufficient data to pivot to other disease diagnosis.

Patent family associated with WO2014206918 (National Phase entry): abandoned

Project terminated, no further activities are carried out

-

Quality Management

-

Additional information

Patents: WO2014206918A1; PCT/EP2014/063117 - Date: Dec 31st, 2014 Status: Granted https://patents.google.com/patent/WO2014206918A1

Privacy Policy
Legal Notice